180 related articles for article (PubMed ID: 26115798)
21. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Valsecchi ME
N Engl J Med; 2015 Sep; 373(13):1270. PubMed ID: 26398077
[No Abstract] [Full Text] [Related]
22. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
23. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Larkin J; Hodi FS; Wolchok JD
N Engl J Med; 2015 Sep; 373(13):1270-1. PubMed ID: 26398076
[No Abstract] [Full Text] [Related]
24. Highlights from the ASCO annual meeting.
Printz C
Cancer; 2013 Sep; 119(17):3104-5. PubMed ID: 24037669
[No Abstract] [Full Text] [Related]
25. Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.
Errico A
Nat Rev Clin Oncol; 2015 Aug; 12(8):435. PubMed ID: 26099982
[No Abstract] [Full Text] [Related]
26. Recent Developments in Melanoma Therapy.
Menzies AM; Long GV
JAMA Oncol; 2016 Oct; 2(10):1259-1260. PubMed ID: 27561103
[No Abstract] [Full Text] [Related]
27. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab.
Wahid M; Akhter N; Jawed A; Dar SA; Mandal RK; Lohani M; Areeshi MY; Khan S; Haque S
Crit Rev Oncol Hematol; 2017 Mar; 111():1-6. PubMed ID: 28259284
[TBL] [Abstract][Full Text] [Related]
29. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma.
Terheyden P; Hofmann MA; Weininger M; Bröcker EB; Becker JC
J Cancer Res Clin Oncol; 2007 Nov; 133(11):897-901. PubMed ID: 17583821
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for treatment of refractory melanoma.
Bagcchi S
Lancet Oncol; 2014 Sep; 15(10):e419. PubMed ID: 25328942
[No Abstract] [Full Text] [Related]
31. Chemotherapy of malignant melanoma.
Nathanson L; Jilani S
Cancer Treat Res; 1993; 65():335-54. PubMed ID: 8104027
[No Abstract] [Full Text] [Related]
32. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
33. [Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer].
Iglesias P; Soria A; Díez JJ
Med Clin (Barc); 2015 Sep; 145(6):264-8. PubMed ID: 25851909
[No Abstract] [Full Text] [Related]
34. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
[TBL] [Abstract][Full Text] [Related]
35. A rapid response to pembrolizumab in a patient with metastatic melanoma.
Bayo Calero J; Aviñó Tarazona V
Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
[TBL] [Abstract][Full Text] [Related]
36. [Medical therapy of malignant melanoma].
Mini E; Periti P
Ann Ital Chir; 1989; 60(4):257-63. PubMed ID: 2699710
[No Abstract] [Full Text] [Related]
37. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy of malignant melanoma].
Karakousis CP
Chirurg; 1986 Oct; 57(10):606-11. PubMed ID: 3792110
[No Abstract] [Full Text] [Related]
40. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
